Am Fam Physician. 2002 Apr 1;65(7):1429-1430.
The salutary effect of angiotensin-converting enzyme (ACE) inhibitors and beta blockers in congestive heart failure (CHF) has been well established in clinical studies. Previous studies have shown that physiologically active levels of angiotensin II persist despite long-term ACE inhibitor therapy. Cohn and Tognoni conducted a randomized, placebo-controlled, double-blind study of 5,010 CHF patients currently receiving either placebo or the angiotensin-receptor blocker (ARB) valsartan in addition to their standard therapy to determine if valsartan could further reduce mortality and morbidity.
ACE inhibitors were being used by 93 percent of study participants, while 35 percent were taking a beta blocker, and 5 percent were taking spironolactone. All patients had CHF documented by echocardiography. Valsartan was initiated at a dosage of 40 mg twice daily, and the dosage was doubled every two weeks until the target dosage of 160 mg twice daily was reached. Dosage increases were stopped if the systolic blood pressure was less than 90 mm Hg while the patient was standing, symptoms of hypotension were present, or the serum creatinine level was greater than 2 mg per dL (180 μmol per L). Patients returned for follow-up visits at two, four, and six months, and every three months thereafter to compare overall mortality rates and the combined outcomes of mortality and morbidity (e.g., hospitalization for heart failure, cardiac arrest with resuscitation, and need for intravenous inotropic or vasodilator drugs for four or more hours without hospitalization).
Overall mortality was not significantly improved by the addition of valsartan. When mortality and morbidity outcomes were combined, 28.8 percent of the valsartan group had an adverse outcome compared to 32.1 percent of participants receiving placebo, giving a relative risk reduction of 13.2 percent. The beneficial effect of valsartan was most pronounced in patients not currently receiving an ACE inhibitor as part of their standard CHF therapy. In the group receiving an ACE inhibitor and a beta blocker at initiation of the study, valsartan had an adverse effect on mortality and was associated with an increase in the combined end points of mortality and morbidity.
The authors concluded that even though there was a relative risk reduction of 13.2 percent in adverse outcomes when valsartan was added to standard CHF therapy, this therapy was potentially harmful in patients receiving an ACE inhibitor and a beta blocker.
BILL ZEPF, M.D.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med. December 6, 2001;345:1667–75.
editor's note: A cursory glance at the abstract of this study might lead one to consider adding an ARB to standard CHF therapy, but it is important once again to emphasize the difference in relative versus absolute risk reductions. The “13.2 percent lower” adverse outcome cited by the authors represents the relative risk reduction, whereas the more important (and perhaps less impressive) number is the 3.3 percent absolute risk reduction, especially when these figures are considered in concert with no overall improvement in mortality and a harmful effect in patients already taking ACE inhibitors and beta blockers.—b.z.
Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions